[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paget-disease-extramammary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paget-disease-extramammary":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,76,121,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100340491","pagetex-photodynamic-therapy-device-for-the-treatment-of-extra-mammary-pagets-disease-of-the-vulva-empv-100340491",false,"NCT03713203","PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).","An Interventional, Phase II, Non Randomized, Mono-centric Study on the Clinical Efficacy and Safety of the Medical Device PAGETEX® as a Photodynamic Therapy Device in the Treatment of Extra-Mammary Paget's Disease of the Vulva (EMPV)","PAGETEX","Inclusion Criteria:\n\n* Non-invasive, primary or recurrent vulvar Paget's disease after surgical resection\n* Ability to give informed consent.\n* Ability to adhere to the study protocol\n* Patients must have biopsy (\\\u003C 1year) proven recurrent extra mammary Paget's disease\n* Effective contraception for Women of childbearing potential\n\nExclusion Criteria:\n\n* Invasive vulvar Paget's Disease\n* Underlying adenocarcinoma\n* Subject to photosensitive disorders \u002F reactions\n* Treatment with Imiquimod \u002F Aldara 5% cream in the last 3 months\n* Photodynamic therapy used to treat MPV lesions in the last 3 months\n* Use of photosensitive agents in the last 3 months\n* Treatment with an experimental drug in the 30 days prior to the start of the study,\n* Allergic or hypersensitivity to methyl aminolevulinate or any of the other ingredients of this medication (propyl p-hydroxybenzoate, cetostearyl alcohol, methyl p-hydroxybenzoate)\n* Allergic or hypersensitivity to peanut or soya due to the presence of peanut oil in Metvixia®\n* Patient with Porphyria\n* Patient already treated with topical corticosteroids on the injured area in the last 3 months\n* Patients with immunity disorders (HIV, transplantation)\n* Clinical follow-up impossible for psychological, family, social or geographical reasons,\n* Legal incapacity\n* Pregnant or lactating woman\n* Refuse to participate in or sign the consent of the study","FEMALE","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","Vulvar Paget's disease is a rare skin tumour which affect Caucasian post-menopausal women. The disease is revealed by erythematous, eczematous, pruritus and vulvar burns. The diagnosis is often late (from a few months to several years) because the symptoms are neglected by patients or misinterpreted by doctors. The reference treatment is based on surgical excision but unfortunately local recurrences are very frequent (17 to 38% of cases).\n\nPhotodynamic therapy (PDT) is already used in some dermatological pathologies and could therefore be an alternative treatment.\n\nThe objective of this study is to assess the efficacy and evaluate the safety of the new PDT device \"PAGETEX\" for the treatment of vulvar Paget's disease.",[27,28],"Paget Disease of the Vulva","Paget Disease, Extramammary",[30,31,32,33],"Photodynamic Therapy (PDT)","Medical Device","Paget Disease","Metvixia®","RECRUITING","2026-04-29",{"date":37,"type":38},"2026-05-05","ACTUAL",{"date":40,"type":38},"2019-08-27",{"date":42,"type":21},"2026-08-27",{"name":44,"class":45},"University Hospital, Lille","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100329073","gynecologic-extramammary-pagets-disease-100329073","NCT03564483","Gynecologic Extramammary Paget's Disease","Prospective Registry of Gynecologic Patients With Extramammary Paget's Disease","Inclusion Criteria:\n\n* Females\n* Age 18 years or older\n* Diagnosed with primary or recurrent EMPD of vulva and\u002For perianal region of the body\n* Willing and able to provide signed informed consent\n\nExclusion Criteria:\n\n* Males\n* Diagnosis of Paget's Disease in body areas other than vulvar or perianal region",{"count":55,"type":21},100,"OBSERVATIONAL","In addition to evaluating treatment outcomes, tissue samples and swabs will be collected as part of this study to allow physicians to better understand Extramammary Paget's Disease (EMPD). The researchers also want to learn more about the microorganisms (microbiome) that live on or near the areas of skin affected by EMPD, in order to better understand this condition.",[59,60,28,61,62,63,64,65,66],"Extramammary Paget's Disease","Extramammary Paget Disease","Extramammary Paget's Disease of Vulva (Diagnosis)","Extramammary Paget's Disease of Vagina (Diagnosis)","Extramammary Paget's Disease Vulva Invasive","Extramammary Paget's Disease of Anus (Diagnosis)","Extramammary Paget's Disease of Anal Canal (Diagnosis)","Extramammary Paget's Disease of Skin","2026-01-26",{"date":69,"type":38},"2026-01-28",{"date":71,"type":38},"2018-02-19",{"date":73,"type":21},"2050-12",{"name":75,"class":45},"Mayo Clinic",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":108,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100568639","phase-2-ivonescimab-in-the-treatment-of-multiple-advanced-tumors-100568639","NCT06683846","Ivonescimab in the Treatment of Multiple Advanced Tumors","Ivonescimab (PD-1\u002FVEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study","Inclusion Criteria:\n\n* Individuals able to understand and give written informed consent.\n* Histologically or cytologically confirmed cancer of one of the following types:\n\nPAGET's disease of scrotum with infiltrating sweat gland carcinoma Paraganglioma Pheochromocytom, Renal angiomyolipoma Malignant perivascular epithelioid cell tumor, Rhabdomyosarcom Other sarcoma rather than rhabdomyosarcom\n\n* Stage IV disease\n* Adequate performance status (ECOG 0-2)\n* Expected survival ≥ 3 months.\n* Measurable disease by CT or MRI, Or lesions with skin infiltration.\n* Adequate hematology without ongoing transfusional support (hemoglobin \\> 9 g\u002FdL, absolute neutrophil count (ANC) \\> 1,500 per mm\\^3, platelets \\> 100,000 per mm\\^3).\n* Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).\n* Adequate coagulation function: International Normalized Ratio (INR) ≤1.5 \u002FPT≤1.5×ULN, aPTT≤1.5×ULN.\n* Willing to use a medically approved contraceptive method from the enrollment to at least 120 days after the end of the study, and sperm donation to another person or cryopreservation for fertilization and reproduction is not permitted during this period.\n* Ability to comply with research visit schedules and other protocol requirements.\n\nExclusion Criteria:\n\n* With any severe and\u002For uncontrolled disease. Including: (1)Poor blood pressure control (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg); (2) poor control of diabetes (fasting blood sugar \\[FBG\\] \\>10mmol\u002FL);\n\n  ≥2 grade myocardial ischemia or myocardial infarction, arrhythmia (QTc≥470ms), and ≥2 grade congestive heart failure (NYHA classification); (3)active or uncontrolled severe infections requiring systemic antibacterial, antifungal, or antiviral treatment (≥CTCAE 2-level infection), including tuberculosis infection; A history of active tuberculosis; (4)Uncontrolled ascites, pleural effusion, or pericardial effusion that require repeated drainage;\n* With active hepatitis (transaminase levels not meeting inclusion criteria; HBV reference: HBV DNA≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; HCV reference: HCV RNA≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; after nucleoside analog antiviral therapy below the above standard, can be included; chronic hepatitis B virus carrier, HBV DNA\\\u003C10\\^4 IU\u002Fml, must be treated with antiviral drugs during the trial period to be eligible for enrollment);\n* History of immunodeficiency, including HIV positive or subjects with other acquired or congenital immunodeficiency diseases;\n* Active autoimmune disease requiring systemic treatment within the past two years, or subjects with an autoimmune disease that the investigator judges may recur or is planned for treatment; except: non-systemic treatment of skin diseases (e.g. vitiligo, alopecia, psoriasis or eczema); autoimmune thyroiditis-induced hypothyroidism requiring stable dose replacement therapy with hormones; 13. Subjects who have experienced severe hypersensitivity reactions after using monoclonal antibodies; individuals who are known to be allergic to the active ingredients or excipients of the study drug;\n* Have participated or are currently participating in another clinical study within the past 4 weeks prior to study entry;\n* Received a live vaccine within the past 30 days prior to the first dose or plan to receive a live vaccine during the study;\n* History of severe allergies;\n* At risk of bleeding, or with impaired coagulation function, or currently receiving thrombolytic therapy;\n* History of substance abuse with an inability to abstain or a history of mental illness;\n* Subjects who, in the opinion of the investigator, have a serious underlying condition that would endanger the subject's safety or impair the subject's ability to complete the study, or who, in the opinion of the investigator, have other reasons not to be enrolled; Subjects who have a history of a clearly defined neurological or psychiatric disorder, such as dementia, epilepsy, or a history of seizure susceptibility;\n* Subjects who, in the opinion of the investigator, have a serious underlying condition that would endanger the subject's safety or impair the subject's ability to complete the study (such as severe diabetes, thyroid disorders, and mental illness), or who have a serious and\u002For unstable medical, psychological, or other condition (including laboratory abnormalities) that would affect the subject's safety or the subject's ability to provide informed consent, or who have any condition that would affect the study protocol and follow-up plan, including psychological, familial, social, or geographic factors;","ALL",{"count":85,"type":21},400,[87],"PHASE2","The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma. cohort 2: Metastatic paraganglioma and pheochromocytoma. cohort 3: Metastatic renal angiomyolipoma and malignant perivascular epithelioid cell tumor.\n\ncohort 4: Rhabdomyosarcoma and Ewing's sarcoma cohort 5: Collecting duct carcinoma cohort 6: Urachal carcinoma. cohort 7: Neuroendocrine cancer. cohort 8: Basal cell carcinoma and sarcomatoid carcinoma. cohort 9: Penile cancer. cohort 10: Adrenal cortical cancer. cohort 11: Metastatic germ cell tumors, failure of standard cisplatin based therapy (mostly testicular cancer).\n\ncohort 12: Non-clear cell renal carcinoma (including renal papillary renal carcinoma); Renal cancer cannot be classified).\n\ncohort 13: Non-clear cell renal carcinoma (including chromophobe renal carcinoma) cohort 14: Other rare tumors that cannot be classified (such as testicular reticulum adenocarcinoma, etc.).\n\ncohort 15: Prostate cancer. cohort 16: Clear cell renal carcinoma. (16.1: received PD-1; 16.2: no PD-1 received) cohort 17: Urothelial carcinoma. cohort 18: Kidney cancer with brain metastases. cohort 19: Brain metastases of urothelial carcinoma. cohort 20: Rare tumors with brain metastases.\n\nIt will also learn about the safety of Ivonescimab. The main questions it aims to answer are:\n\nDoes Ivonescimab improve the objective response rate and prolong the survival of participants? What medical problems do participants have when taking Ivonescimab?\n\nParticipants will:\n\nReceive Ivonescimab 20mg\u002Fkg intravenously every 21 days until disease progression, intolerable toxicity, or full 2 years of treatment, whichever occurs first.\n\nBe performed imaging evaluation according to RECIST 1.1 every 9 weeks for 1 year of treatment and every 12 weeks after 1 year Be recorded any adverse events in the whole study period including type, incidence, grade, severity, duration, and association with the study drug according to NCI-CTCAE V5.0 criteria",[90,91,28,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107],"Pheochromocytoma\u002FParaganglioma","Rhabdomyosarcoma","Renal Angiomyolipoma","Perivascular Epithelioid Cell Tumor, Malignant","Sarcoma","Urachal Cancer","Neuroendocrine Cancer","Basal Cell Carcinomas","Sarcomatoid Carcinoma","Penile Cancer","Adrenal Cortical Cancer","Germ Cell Cancer Metastatic","Non-Clear Cell Renal Cell Carcinoma","Prostate Cancers","Clear Cell Renal Cancer","Urothelial Carcinoma","Kidney Cancer","Rare Tumors",[109,110,111],"rare tumor","Ivocizumab","immunotherapy","2025-08-19",{"date":114,"type":38},"2025-08-24",{"date":116,"type":38},"2024-11-20",{"date":118,"type":21},"2027-11-30",{"name":120,"class":45},"Fudan University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":129,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":46},"100576882","phase-2-a-study-of-rc48-adc-combined-with-js001-for-advanced-extramammary-paget-disease-of-the-scrotum-100576882","NCT06791070","A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum","A Prospective Multicenter Clinical Trial on the Efficacy and Safety of RC48-ADC (Disitamab Vedotin) Combined With Toripalimab in Advanced HER2-positive Extramammary Paget Disease of the Scrotum","RC48&J for EPD","Inclusion Criteria:\n\nVoluntarily sign the informed consent form and comply with the requirements of the protocol.\n\nAge ≥ 18 years old. Confirmed diagnosis by histological examination, combined with imaging assessment for scrotal extramammary Paget's disease; pathologically confirmed as HER2 positive, i.e., immunohistochemical test HER2 ≥ 1+.\n\nECOG score: 0 to 1. At least one measurable lesion (according to the RECIST criteria, non-nodal lesions with a longest diameter on CT scan ≥10 mm, and nodal lesions with a shortest diameter on CT scan ≥15 mm); or skin lesions that can be evaluated according to the WHO criteria.\n\nAdequate organ function: Blood routine: Absolute Neutrophil Count (ANC) ≥1.5×10\\^9\u002FL, Platelet (PLT) ≥70×10\\^9\u002FL, Hemoglobin (HGB) ≥80g\u002FL; Liver function: Total Bilirubin (TBIL) ≤1.5×Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤3×ULN; Serum Albumin ≥28 g\u002FL; Alkaline Phosphatase (ALP) ≤5×ULN; If the subject has received routine liver protection treatment and meets the above standards, and is stable for at least one week after assessment by the researcher, they may be enrolled; Renal function: Serum Creatinine (Cr) ≤1.5×ULN, or Creatinine Clearance ≥50 mL\u002Fmin (using the standard Cockcroft-Gault formula): Coagulation function: International Normalized Ratio (INR) ≤1.5 \u002F Prothrombin Time (PT) ≤1.5×ULN, Activated Partial Thromboplastin Time (aPTT) ≤1.5×ULN; If the subject is receiving anticoagulant therapy, as long as PT and INR are within the range specified for the anticoagulant medication, it is acceptable.\n\nEstimated life expectancy ≥3 months.\n\nExclusion Criteria:\n\nHave a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; Have had active autoimmune diseases within 2 years prior to the start of the study treatment that required systemic treatment (such as the use of disease-modifying drugs, corticosteroids, or immunosuppressants), except for replacement therapies (e.g., thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency); currently receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy. The dose is \\>10mg\u002Fday of prednisone or other equivalent hormones, and it is within 2 weeks of the first administration and still in use; Have a history of active tuberculosis; Have uncontrollable, recurrent drainage of ascites, pericardial effusion, or pleural effusion; Have undergone major organ transplantation; Received major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of the study treatment; or have chronic non-healing wounds or fractures; Have a history of live attenuated vaccine administration within 14 days prior to the start of the study treatment or plan to receive live attenuated vaccine vaccination during the study period; Have had a severe hypersensitivity reaction after the use of monoclonal antibodies; known allergy to the active ingredients or excipients of this study drug; Within 4 weeks prior to the start of the study, are participating in or have participated in other clinical studies; Have a history of severe allergies; Have a risk of bleeding, or coagulation dysfunction, or are currently receiving -thrombolytic therapy; Have a history of substance abuse and are unable to quit or have mental disorders; According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study, or there are other reasons deemed unsuitable for enrollment by the investigator.","MALE","80 Years",{"count":132,"type":21},20,[87],"The goal of this clinical trial is to learn if Disitamab Vedotin combined with Toripalimab works to treat advanced HER2-positive extramammary Paget disease of the scrotum. It will also learn about the safety of this combination. The main questions it aims to answer are: Does this combination reduce tumor volume and delay disease progression? What medical problems do participants have when receving this combination? Participants will: Intravenous using this combination every 3 weeks until disease progression or intolerable adverse reactions occur. Visit the clinic once every 3 weeks for checkups and tests.",[28,136],"Scrotum Disease",[138,139,140,141],"extramammary Paget disease","Disitamab Vedotin","Toripalimab","RC48-ADC","2025-01-19",{"date":144,"type":38},"2025-01-24",{"date":146,"type":21},"2025-01",{"date":148,"type":21},"2028-01",{"name":150,"class":45},"Fujian Medical University Union Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":46},"100568676","phase-2-multi-cohort-single-arm-phase-ii-study-of-albumin-paclitaxel-ifosfamide-and-cisplatin-in-the-treatment-of-rare-advanced-tumors-100568676","NCT06684327","Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors","Inclusion Criteria:\n\n* Individuals able to understand and give written informed consent.\n* Histologically or cytologically confirmed cancer of one of the following types:\n\nPAGET's disease of scrotum with infiltrating sweat gland carcinoma Rhabdomyosarcoma Testicular cancer Penile cancer Urachal cancer\n\n* Stage IV disease\n* Adequate performance status (ECOG 0-2)\n* Expected survival ≥ 3 months.\n* Measurable disease by CT or MRI, Or lesions with skin infiltration.\n* Adequate hematology without ongoing transfusional support (hemoglobin \\> 9 g\u002FdL, absolute neutrophil count (ANC) \\> 1,500 per mm\\^3, platelets \\> 100,000 per mm\\^3).\n* Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).\n* Adequate coagulation function: International Normalized Ratio (INR) ≤1.5 \u002FPT≤1.5×ULN, aPTT≤1.5×ULN.\n* Willing to use a medically approved contraceptive method from the enrollment to at least 120 days after the end of the study, and sperm donation to another person or cryopreservation for fertilization and reproduction is not permitted during this period.\n* Ability to comply with research visit schedules and other protocol requirements.\n\nExclusion Criteria:\n\n* 1\\. Active or uncontrolled severe infections (≥CTCAE Level 2) requiring systemic antibacterial, antifungal, or antiviral therapy, including tuberculosis infections.\n* 2\\. Active hepatitis (transaminases not within inclusion criteria; HBV reference: HBV DNA ≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; HCV reference: HCV RNA ≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; after nucleoside antiviral treatment below the above standards, may be eligible; chronic HBV carrier with HBV DNA \\\u003C10\\^4 IU\u002Fml, must receive antiviral treatment during the study period to be eligible).\n* 3\\. Renal failure requiring hemodialysis or peritoneal dialysis.\n* 4\\. History of immunodeficiency, including HIV positive or having other acquired\u002Fcongenital immunodeficiency diseases, or organ transplant history.\n* 5\\. Severe nausea, headache, insomnia, fatigue, somnolence, dry mouth, dizziness, and constipation.\n* 6\\. History of active tuberculosis.\n* 7\\. Uncontrolled ascites, pleural effusion, or pericardial effusion requiring repeated drainage.\n* 8\\. Patients who have undergone major organ transplantation.\n* 9\\. Individuals who have undergone major surgical procedures, open biopsies, or obvious traumatic injuries within 28 days prior to the start of the study; or have unhealed wounds or fractures for a long time;\n* 10\\. Individuals who have participated or are currently participating in another clinical study within the past 4 weeks prior to the start of the study;\n* 11\\. Individuals with a history of severe allergies;\n* 12\\. Individuals at risk of bleeding, or with impaired coagulation function, or who are currently receiving thrombolytic therapy;\n* 13\\. Individuals with a history of substance abuse with no ability to abstain or with a mental disorder.\n* 14\\. According to the investigator's judgment, subjects with serious adverse effects on their safety or completion of the study, or those with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or those with other reasons deemed unsuitable for enrollment by the investigator. Subjects with a history of a clearly defined neurological or psychiatric disorder, such as dementia, epilepsy, or a history of epilepsy prone.",{"count":55,"type":21},[87],"The goal of this clinical trial is to learn if albumin-paclitaxel, ifosfamide and cisplatin (Nab-TIP) works to treat advanced rare tumors including PAGET's disease of scrotum with infiltrating sweat gland carcinoma （cohort 1）, rhabdomyosarcoma (cohort 2), testicular cancer (cohort 3), penile cancer (cohort 4), and urachus cancer (cohort 5) . It will also learn about the safety of Nab-TIP. The main questions it aims to answer are:\n\nDoes Nab-TIP improve the objective response rate and prolong the survival of participants? What medical problems do participants have when receiving the regimen of Nab-TIP?\n\nParticipants will:\n\nReceive albumin-paclitaxel 260mg\u002Fm2 d1, isocyclophosphamide 1500mg\u002Fm2 d2-5, and cisplatin 25mg\u002Fm2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.\n\nBe performed imaging evaluation according to RECIST 1.1 every 6 weeks for 1 year of treatment and every 12 weeks after 1 year Be recorded any adverse events in the whole study period including type, incidence, grade, severity, duration, and association with the study drug according to NCI-CTCAE V5.0 criteria",[28,91,161,99,95],"Testicular Cancer",[109,163,164,165],"albumin-paclitaxel","ifosfamide","cisplatin","2024-12-18",{"date":168,"type":38},"2024-12-20",{"date":170,"type":38},"2024-11-30",{"date":172,"type":21},"2027-12-30",{"name":120,"class":45}]